Taro Provides Results for Year Ended March 31, 2017
Quarter ended
- Net sales of
$196.4 million , decreased$68.7 million , or 25.9%, the result of continuing increased competition and the challenging pricing environment. Overall volumes increased 3%. - Gross profit of
$143.8 million decreased$80.4 million , and as a percentage of net sales, was 73.2% compared to 84.6% for the same quarter last year. - Research and development expenses of
$19.9 million , remained in line with the comparable quarter. - Selling, marketing, general and administrative expenses (SG&A) of
$22.2 million slightly decreased. - Operating income of
$101.7 million decreased$80.0 million and as a percentage of net sales was 51.8% as compared to 68.6% in the prior year quarter. - Foreign Exchange (FX) expense decreased
$41.6 million to $5.8 million , principally due to the weakening of the U.S. dollar vs. Canadian dollar at a lower rate than in prior period. - Tax expense decreased
$5.6 million to $17.3 million resulting in an effective tax rate of 17.3% compared to 16.6% for the same quarter last year. - Net Income attributable to Taro was
$83.0 million compared to$115.0 million , resulting in diluted earnings per share of$2.05 compared to$2.68 for the same period last year.
Year ended
- Net sales of
$879.4 million , decreased$71.4 million , or 7.5%. Overall volumes increased 2% versus the prior year. - Gross profit of
$671.3 million decreased$107.7 million and as a percentage of net sales, was 76.3% compared to 81.9%. - Research and development expenses of
$70.6 million decreased slightly. - SG&A expenses decreased
$6.7 million to $85.7 million , principally as a result of reduced Keveyis spend and certain other savings. - Operating income of
$515.0 million decreased$99.5 million , and as a percentage of net sales was 58.6% vs. 64.6%. - FX income increased
$13.1 million to $20.2 million , principally driven by the strengthening of the U.S. dollar vs. Canadian dollar at a slightly lower rate compared to the prior year. The FX impact is mainly balance sheet driven. - Other gain, net of
$11.2 million increased$8.5 million , primarily driven by the sale of Keveyis in the fiscal 2017 third quarter. - Tax expense increased
$8.5 million , mainly due to certain tax benefits reflected in the prior year, not realized in the current year, resulting in the effective tax rate increasing to 18.5% from 15.0%. - Net income attributable to Taro was
$456.4 million compared to$540.9 million , resulting in diluted earnings per share of$11.05 compared to$12.62 for last year.
Cash Flow and Balance Sheet Highlights - compared to
- Cash provided by operations for the period ended
March 31, 2017 was$437.5 million , compared to$395.1 million . - As of
March 31, 2017 , cash, including short-term bank deposits and marketable securities of$1.4 billion , increased$158.1 million fromMarch 31, 2016 , despite the$294.9 million impact from the Company’s share repurchases during this fiscal year.
Mr.
FDA Approvals and Filings
The Company recently received approvals from the
Share Repurchase Program - Returning Capital to Shareholders
On
Under the
Purchase of
On
Development and Commercialization license to sell and distribute Pliaglis®
On
Earnings Call (
As previously announced, the Company will host an earnings call at
- Participant Toll-Free Dial-In Number: +1 (844) 421-0601 ID: 21985230
- Participant International Dial-In Number: +1 (716) 247-5800 ID: 21985230
- Web-cast: More details are provided on our website, www.taro.com
To participate in the audio call, please dial the numbers provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. The transcript of the event will be available on the Company’s website at www.taro.com. An audio playback will be available for twenty four (24) days following the call.
About Taro
SAFE HARBOR STATEMENT
The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company. The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2018. Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained. Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in
**Financial Tables Follow**
TARO PHARMACEUTICAL INDUSTRIES LTD. | |||||||||||||||||||||
SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||||||
(U.S. dollars in thousands, except share data) | |||||||||||||||||||||
Quarter Ended | Year Ended | ||||||||||||||||||||
March 31, | March 31, | ||||||||||||||||||||
2017 |
2016 |
2017 |
2016 |
||||||||||||||||||
(unaudited) | (unaudited) | (unaudited) | (audited) | ||||||||||||||||||
Sales, net | $ | 196,414 | $ | 265,073 | $ | 879,387 | $ | 950,751 | |||||||||||||
Cost of sales | 52,494 | 40,749 | 207,860 | 169,743 | |||||||||||||||||
Impairment | 92 | 95 | 276 | 2,042 | |||||||||||||||||
Gross profit | 143,828 | 224,229 | 671,251 | 778,966 | |||||||||||||||||
Operating Expenses: | |||||||||||||||||||||
Research and development | 19,878 | 19,948 | 70,644 | 71,160 | |||||||||||||||||
Selling, marketing, general and administrative | 22,206 | 22,561 | 85,656 | 92,365 | |||||||||||||||||
Settlements and loss contingencies | — | — | — | 973 | |||||||||||||||||
Operating income | 101,744 | 181,720 | 514,951 | 614,468 | |||||||||||||||||
Financial (income) expense, net: | |||||||||||||||||||||
Interest and other financial income | (3,654 | ) | (2,896 | ) | (14,468 | ) | (12,604 | ) | |||||||||||||
Foreign exchange expense (income) | 5,830 | 47,478 | (20,168 | ) | (7,068 | ) | |||||||||||||||
Other gain, net | 745 | 860 | 11,211 | 2,680 | |||||||||||||||||
Income before income taxes | 100,313 | 137,999 | 560,798 | 636,820 | |||||||||||||||||
Tax expense | 17,313 | 22,950 | 103,780 | 95,313 | |||||||||||||||||
Income from continuing operations | 83,000 | 115,049 | 457,018 | 541,507 | |||||||||||||||||
Net loss from discontinued operations attributable to Taro | (38 | ) | (34 | ) | (352 | ) | (236 | ) | |||||||||||||
Net income | 82,962 | 115,015 | 456,666 | 541,271 | |||||||||||||||||
Net (loss) income attributable to non-controlling interest | (23 | ) | 65 | 310 | 339 | ||||||||||||||||
Net income attributable to Taro | $ | 82,985 | $ | 114,950 | $ | 456,356 | $ | 540,932 | |||||||||||||
Net income per ordinary share from continuing |
|||||||||||||||||||||
Basic | $ | 2.05 | $ | 2.68 | $ | 11.06 | $ | 12.63 | |||||||||||||
Diluted | $ | 2.05 | $ | 2.68 | $ | 11.06 | $ | 12.63 | |||||||||||||
Net loss per ordinary share from discontinued |
|||||||||||||||||||||
Basic | $ | (0.00 | ) | * | $ | (0.00 | ) | * | $ | (0.01 | ) | $ | (0.01 | ) | |||||||
Diluted | $ | (0.00 | ) | * | $ | (0.00 | ) | * | $ | (0.01 | ) | $ | (0.01 | ) | |||||||
Net income per ordinary share attributable to Taro: | |||||||||||||||||||||
Basic | $ | 2.05 | $ | 2.68 | $ | 11.05 | $ | 12.62 | |||||||||||||
Diluted | $ | 2.05 | $ | 2.68 | $ | 11.05 | $ | 12.62 | |||||||||||||
Weighted-average number of shares used to compute net |
|||||||||||||||||||||
Basic | 40,566,815 | 42,828,338 | 41,300,797 | 42,832,241 | |||||||||||||||||
Diluted | 40,566,815 | 42,828,338 | 41,300,797 | 42,832,241 | |||||||||||||||||
* Amount is less than $0.01 | |||||||||||||||||||||
May not foot due to rounding. | |||||||||||||||||||||
TARO PHARMACEUTICAL INDUSTRIES LTD. | |||||||||
SUMMARY CONSOLIDATED BALANCE SHEETS | |||||||||
(U.S. dollars in thousands) | |||||||||
March 31, | March 31, | ||||||||
2017 | 2016 | ||||||||
ASSETS | (unaudited) | (audited) | |||||||
CURRENT ASSETS: | |||||||||
Cash and cash equivalents | $ | 600,399 | $ | 576,757 | |||||
Short-term and current maturities of long-term bank deposits | 782,813 | 648,297 | |||||||
Marketable securities | 3,548 | 3,572 | |||||||
Accounts receivable and other: | |||||||||
Trade, net | 203,924 | 238,611 | |||||||
Other receivables and prepaid expenses | 266,280 | 270,724 | |||||||
Inventories | 141,045 | 138,553 | |||||||
Long-term assets held for sale, net | 1,015 | 1,081 | |||||||
TOTAL CURRENT ASSETS | 1,999,024 | 1,877,595 | |||||||
Long-term bank deposits | 70,685 | 115,173 | |||||||
Property, plant and equipment, net | 180,085 | 159,459 | |||||||
Other assets | 39,959 | 35,806 | |||||||
TOTAL ASSETS | $ | 2,289,753 | $ | 2,188,033 | |||||
LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||||
CURRENT LIABILITIES: | |||||||||
Trade payables and other current liabilities | $ | 209,837 | $ | 245,462 | |||||
TOTAL CURRENT LIABILITIES | 209,837 | 245,462 | |||||||
Deferred taxes and other long-term liabilities | 6,110 | 5,427 | |||||||
TOTAL LIABILITIES | 215,947 | 250,889 | |||||||
Taro shareholders' equity | 2,067,494 | 1,931,142 | |||||||
Non-controlling interest | 6,312 | 6,002 | |||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 2,289,753 | $ | 2,188,033 | |||||
TARO PHARMACEUTICAL INDUSTRIES LTD. | |||||||||||
SUMMARY CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||
(U.S. dollars in thousands) | |||||||||||
Year Ended March 31, | |||||||||||
2017 | 2016 | ||||||||||
Cash flows from operating activities: | (unaudited) | (audited) | |||||||||
Net income | $ | 456,666 | $ | 541,271 | |||||||
Adjustments required to reconcile net income to net cash provided by operating activities: | |||||||||||
Depreciation and amortization | 14,829 | 14,848 | |||||||||
Impairment for long-lived assets | 276 | 2,042 | |||||||||
Realized (gain) loss on sale of marketable securities and long-lived assets | (8,389 | ) | 74 | ||||||||
Change in derivative instruments, net | 1,434 | (6,137 | ) | ||||||||
Effect of change in exchange rate on inter-company balances and bank deposits | (21,174 | ) | (7,778 | ) | |||||||
Deferred income taxes, net | 73,706 | (11,976 | ) | ||||||||
Decrease (increase) in trade receivables, net | 34,413 | (16,386 | ) | ||||||||
Increase in inventories, net | (3,770 | ) | (19,013 | ) | |||||||
Increase in other receivables, income tax receivable, prepaid expenses and other | (75,219 | ) | (42,858 | ) | |||||||
Decrease in trade, income tax, accrued expenses, and other payables | (35,237 | ) | (58,959 | ) | |||||||
Net cash provided by operating activities | 437,535 | 395,128 | |||||||||
Cash flows from investing activities: | |||||||||||
Purchase of plant, property & equipment, net | (35,755 | ) | (18,972 | ) | |||||||
Proceeds from (investment in) other intangible assets | 8,440 | (134 | ) | ||||||||
Proceeds from other assets | — | 35,000 | |||||||||
Proceeds from (investment in) short-term bank deposits | 196,170 | (220,102 | ) | ||||||||
Investment in long-term deposits and other assets | (286,607 | ) | (80,587 | ) | |||||||
Proceeds from restricted bank deposits | — | 199 | |||||||||
Investment in marketable securities, net | (26 | ) | (135 | ) | |||||||
Net cash used in investing activities | (117,778 | ) | (284,731 | ) | |||||||
Cash flows from financing activities: | |||||||||||
Purchase of treasury stock | (294,897 | ) | (9,450 | ) | |||||||
Repayment of long-term debt | — | (5,888 | ) | ||||||||
Net cash used in financing activities | (294,897 | ) | (15,338 | ) | |||||||
Effect of exchange rate changes on cash and cash equivalents | (1,218 | ) | 57 | ||||||||
Increase in cash and cash equivalents | 23,642 | 95,116 | |||||||||
Cash and cash equivalents at beginning of period | 576,757 | 481,641 | |||||||||
Cash and cash equivalents at end of period | $ | 600,399 | $ | 576,757 | |||||||
Cash Paid during the year for: | |||||||||||
Interest | $ | — | $ | 85 | |||||||
Income taxes | $ | 97,782 | $ | 192,964 | |||||||
Non-cash investing transactions: | |||||||||||
Purchase of property, plant and equipment included in accounts payable | $ | 692 | $ | 1,744 | |||||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522006433/en/
Source:
Taro Pharmaceutical Industries Ltd.
Mariano A. Balaguer, 914-345-9001
VP, Chief Financial Officer and Chief Accounting Officer
Mariano.Balaguer@taro.com
or
William J. Coote, 914-345-9001
AVP, Business Finance, Treasurer and Investor Relations
William.Coote@taro.com